Immunoflazid

Immunoflazid - an antiviral drug that has direct medicinal effects. Included in the category of immunomodulators and cytokines.

[1]

Indications of the immunoflazid

It is used in the following situations:

• for elimination of ARVI or as a preventive measure for their development;
• for the prevention or elimination of influenza (this includes strains of pandemic type);
• as an integral part of combined treatment for development of influenza-associated or other acute respiratory viral complications of bacterial type.

Release form

Release in the form of a syrup, in plastic or glass bottles in volume 30, 50, 60 or 125 ml. Inside the pack - 1 bottle of syrup, complete with a special dispenser.

[2]

Pharmacodynamics

The flavonoids found in the drug can inhibit the replication of viral RNA and DNA both in vitro and in vivo. During the preclinical, as well as clinical tests, the slowing activity of Immunoflazid against herpes and influenza viruses, as well as ARVI, was noted.

It is known that the direct antiviral effect of the drug is due to inhibition of the binding of enzymes to specific viral parameters - RNA and DNA polymerases, and in addition to the reverse transcriptase with thymidine kinase and neuraminidase. Also, the mechanism of action involves induction of the binding of internal interferon.

The drug helps protect mucous membranes in the upper part of the respiratory system, stabilizing local immune parameters (lactoferrin substances with lysozyme, as well as slgA).

During the tests, it was found that Immunoflazid helps normalize the binding of internal α- as well as γ-interferons (in physiologically active values), and in addition increases the nonspecific resistance of the organism with respect to infections of bacterial and viral origin.

Along with this, during the tests it was possible to find out that in the case of everyday use of the syrup taking into account the age dosages, as well as the regimens of use, the immune refractoriness does not develop: there is no suppression of the α- and γ-interferon binding processes. This property of the drug helps to maintain the interferon indices at the level that is required for the appropriate immune response of the body to infection. This circumstance allows, if necessary, to use the medicine with long courses.

The drug has an antioxidant effect and the ability to slow the flow of free radical processes, which prevents the cumulation of products of lipid peroxidation, increasing the cellular antioxidant level. Together with this, it also reduces intoxication and helps restore the body's activity weakened by the transmitted infection and adapt it to unfavorable environmental factors.

The drug modulates the process of apoptosis: it potentiates the activity of apoptosis-inducing factors, enhancing the effect of caspase 9. This helps to speed up the process of eliminating cells that have been affected by the virus. Along with this, the drug acts as a means of primary prevention of the development of chronic pathologies against the background of hidden infections of viral genesis.

Pharmacokinetics

The active component of the drug is quickly absorbed into the body from the digestive tract, and its peak is observed after 20 minutes from the time of taking (in vivo tests).

After taking the syrup, the bioavailability of the substance is 80%.

In accordance with the available dynamics, the plasma half-life is about 2.3 hours. The excretion of the substance is rather slow.

The indicator of cumulation of drug components inside blood cells is higher than their level inside the plasma. Corresponding values of drugs help to prolong the period of drug exposure, as well as its cumulation inside tissues with organs, by releasing blood cells from them. Existing pharmacokinetic values of cumulation and release of active substances from blood cells necessitate a 2-day application of Immunoflazide per day - to obtain drug-effective drug concentrations.

Dosing and administration

It is required to shake the bottle with the medicine before taking the syrup.

Doses are measured with a dispenser, and the use of syrup should occur before meals - about 20-30 minutes.

In order to achieve a stronger drug effect during exposure to respiratory viruses, it is recommended to hold the syrup in the mouth for about 20-30 seconds, and rinse with a throat before swallowing.

Duration of therapy and dose sizes are calculated taking into account the age of the patient, as well as the nature of the pathology.

Dosage regimens and dosages of Immunoflazide:

• infants up to 1 year: take 0.5 ml of syrup twice per day;
• children 1-2 years: taking 1 ml of syrup 2 times a day;
• children 2-4 years: the use of 3 ml of syrup twice a day;
• children 4-6 years of age: use of 4 ml of medication 2 times a day;
• children 6-9 years: taking 5 ml of the drug twice a day;
• children 9-12 years of age: the use of 6 ml of medication 2 times a day;
• adolescents from 12 and adults: taking 9 ml of syrup twice a day.

For elimination of acute respiratory viral infection and influenza (if the disease runs without resting), it is necessary to drink syrup for 5 days. To increase the effectiveness of the drug, it is necessary to begin its reception immediately after the appearance of the first signs of the disease or immediately after contact with already infected people. Taking into account the course of pathology, it may also be decided to extend the course to 14 days.

As a prophylactic for ARVI and influenza, the drug is drunk during 1-4 weeks at a dosage equal to half the standard drug.

In the period of pandemic epidemics, the duration of syrup intake for prevention can be increased to 1.5 months.

If the patient has bacterial complications (with influenza or other ARVI), you can take the syrup during the first month and longer - to stabilize the immune parameters.

[3]

Use of the immunoflazid during pregnancy

During the preclinical testing, no mutagenic, feto-embryotoxic, or teratogenic effects on the fetus were detected. There was no adverse effect when using Immunoflazid at the 1 st and 3 rd trimesters, as well as during lactation, but it is still recommended to be guided by the risk / benefit considerations before deciding on taking the drug, and also consulting the treating doctor.

Contraindications

The main contraindications:

• intolerance of the constituent elements of the drug;
• exacerbated ulcer in the area of the 12-intestine or stomach;
• pathology of the autoimmune type.

Side effects of the immunoflazid

The intake of syrup usually does not lead to the development of side effects. There were isolated abnormalities in the gastrointestinal tract: nausea, epigastric pain, diarrhea, and vomiting (if these manifestations develop, you need to drink syrup 1.5-2 hours after eating). 3-10 day course of treatment a transient increase in temperature may be observed up to 38 ^{of the} S.

People with gastroduodenitis in the chronic stage may develop an exacerbation of this disease, as well as GERD.

Sometimes there are manifestations of hypersensitivity and signs of allergy (mainly in the form of rash erythematous type).

Occasionally there are headaches - they pass after a change in dosage, as well as a scheme for taking syrup.

If any negative symptoms develop, consult a doctor.

Interactions with other drugs

With medicinal use, the possibility of combining the drug with antibiotics, as well as with antimycotics to eliminate pathologies of the viral-fungal and viral-bacterial genesis, has been established. Negative effects during drug interaction with other medications were not observed.

[4], [5]

Storage conditions

The syrup should be kept in a dark place, where small children can not penetrate. The temperature conditions are not more than 25 ° C. Do not freeze the medicine. The opened vial should be stored in a dark place, closed.

Special instructions

Reviews

Immunoflazid receives conflicting reviews about its effectiveness - to someone it turns out to be very useful, and someone has no result from taking drugs. But on the whole, positive reviews outweigh. Parents note that the syrup helps to improve the immunity of the child, as well as the fact that the children enjoy his taste.

Of the shortcomings, a high enough cost is allocated, as well as frequent cases of the appearance of allergic reactions to drug use. Inconvenience is also considered that a drug in an already opened vial can be stored for a maximum of 30 days. But this problem is solved by the availability of the opportunity to purchase a bottle of smaller volume.

Shelf life

Immunoflazid is allowed to be used in the period of 2 years from the date of release of the syrup. The opened bottle has a shelf life of a maximum of 30 days.